Our findings suggest that improving muscle function and muscle mass is an encouraging precaution against cardiometabolic diseases and Alzheimer's disease, with particular emphasis on insulin resistance as an essential target in the prevention and intervention of sarcopenia‐related cardiometabolic risk. This evidence concerns the gene INS and Alzheimer disease.